Embark Early Education (ASX: EVO) Is Offering 6.8% Fully-Franked Dividend Yield, Should You Buy Its Shares?
We see HY2025 as the first genuinely credible step in EVO’s multi-year turnaround. Not a cosmetic clean-up. Not a one-off bounce. A real shift. Occupancy is climbing, labour stability is improving, centre-level margins are widening, and cashflow finally has the shape of something we can underwrite. Management has been making tough decisions — cutting deadweight centres, fixing staffing inconsistencies, and rebuilding trust in local communities — and the P&L now reflects it.
How much lower could Hot Chili’s (ASX: HCH) recently started downtrend take the share price?
Hot Chili Limited is a pre-revenue copper developer focused on its large-scale Costa Fuego project in Chile, supported by strategic water infrastructure and long-term exposure to the global copper supply deficit theme. However, its recent share price weakness has been driven by a discounted capital raising, ongoing dilution risk, high cash burn, valuation concerns, and broader copper-sector volatility. Technically, the stock has entered a correction phase, with downside support levels around A$1.25–1.30, A$1.15 and near A$1.00, while a sustained break below the A$0.80–0.90 zone would signal a deeper trend reversal.
Acrow Limited (ASX: ACF): Is This Growing Equipment Rental Business a Buy in Oversold Territory?
Acrow Limited is an Australian engineering and equipment rental company supplying formwork and scaffolding to construction and infrastructure projects. The business generates recurring income from its large hire fleet and has delivered strong revenue growth in recent years. Despite recent share price weakness, it offers solid cash flow and a fully franked dividend yield above 5%.
Is Orthocell's (ASX: OCC) Recent Share Price Decline a Warning Sign or a Buying Signal?
Orthocell is a regenerative medicine company expanding Remplir globally, but investors remain cautious because revenue growth is uneven, the business is still loss-making, and U.S. uptake may take time, leaving the stock a higher-risk turnaround opportunity.
What is the reason for the plummet in Dimerix (ASX: DXB) share price, and how much lower can it go?
Dimerix shares plunged 35–40% amid heavy selling and uncertainty around clinical updates, worsened by weak biotech sentiment. Further downside depends on results and the funding outlook, though volatility in early-stage biotech stocks suggests a potential for sharp rebounds.
Resolution Minerals (ASX: RML) Surges on Fresh Catalysts; Share Price Rebounds Strongly
Resolution Minerals (ASX: RML) has rebounded from $0.04 toward $0.07–$0.08, driven by U.S. critical minerals progress and rising investor interest. Despite volatility, strong project developments, infrastructure moves, and drilling activity are shifting sentiment and supporting renewed momentum.